Comment on Hempe Et Al. The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. Diabetes Care 2015;38:1067–1074

Diabetes Care- United States

doi 10.2337/dc15-1073

Full Text

Abstract

Available in

Date

September 24, 2015

Authors

Matthew C. Riddle

Hertzel C. Gerstein

Publisher

American Diabetes Association

Related search

Comment on Lee Et Al. Diabetes 2015;64:2836–2846. Comment on Roberts Et Al. Diabetes 2015;64:471–484

French

Response to Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. InStandards of Medical Care in Diabetes—2015. Diabetes Care 2015;38(Suppl. 1):S41–S48

English

Response to Comment on Evron Et Al. Changes in Screening Practices for Prediabetes and Diabetes Since the Recommendation for Hemoglobin A1c Testing. Diabetes Care 2019;42:576–584

English

Response to Comment on Trinh Et Al. Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes With Infliximab. Diabetes Care 2019;42:e153–e154

English

Comment on Young-Hyman Et Al. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140

English

Monitoring Emerging Prescription-Drug Related Harms: A Comment on Cairns Et Al . (2018)

English

Comment on Timmers Et Al. Resveratrol as Add-On Therapy in Subjects With Well-Controlled Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care 2016;39:2211–2217

English

The Haemoglobin Glycation Index as Predictor of Diabetes-Related Complications in the AleCardio Trial

European Journal of Preventive Cardiology

Epidemiology

Cardiovascular Medicine

Cardiology

2017

English

Comment on Bress Et Al. Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes Care 2017;40:1401–1408

English

Amanote Research

Comment on Hempe Et Al. The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. Diabetes Care 2015;38:1067–1074

Diabetes Care- United States

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Comment on Lee Et Al. Diabetes 2015;64:2836–2846. Comment on Roberts Et Al. Diabetes 2015;64:471–484

Response to Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. InStandards of Medical Care in Diabetes—2015. Diabetes Care 2015;38(Suppl. 1):S41–S48

Response to Comment on Evron Et Al. Changes in Screening Practices for Prediabetes and Diabetes Since the Recommendation for Hemoglobin A1c Testing. Diabetes Care 2019;42:576–584

Response to Comment on Trinh Et Al. Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes With Infliximab. Diabetes Care 2019;42:e153–e154

Comment on Young-Hyman Et Al. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140

Monitoring Emerging Prescription-Drug Related Harms: A Comment on Cairns Et Al . (2018)

Comment on Timmers Et Al. Resveratrol as Add-On Therapy in Subjects With Well-Controlled Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care 2016;39:2211–2217

The Haemoglobin Glycation Index as Predictor of Diabetes-Related Complications in the AleCardio Trial

Comment on Bress Et Al. Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes Care 2017;40:1401–1408